Latham & Watkins Advises on CervoMed’s Private Placement Financing

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders (the Company), has announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units (the Units), each Unit composed of (i) (A) one share of its common stock or (B) one pre-funded warrant to purchase shares of its common stock, and in each case, (ii) one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement. A Unit composed of one share of common stock and one Series A warrant shall have a purchase price of US$19.745 and a Unit composed of one pre-funded warrant and one Series A warrant shall have a purchase price of US$19.744.

Latham & Watkins advised the placement agents in the financing, with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Kathleen Mehary and Sheen Moaleman.